ReviewFrontiers in oncology2025
Vorasidenib for IDH-mutant grade 2 gliomas: clinical advances and future directions.
Zhenjiang Pan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it
ReviewFrontiers in oncology2025
Zhenjiang Pan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.